HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.
September 21, 2023 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics (NASDAQ:RGLS) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $9.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Regulus Therapeutics. The maintained price target of $9 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100